MEN2: RET gene, sequencing analysis

Alphabetical Test listing

MEN2: RET gene, sequencing analysis-994

  
MEN2: RET gene, sequencing analysis
  
994
  
LAB994
  
MSO
  

This test can be used to identify genetic variations in the RET gene that are causative for MEN2.

  
EDTA whole blood
  
  
3.0 mL
  
1.0 mL
Submitting the minimum volume does not allow for repeat testing
  

Lavender (EDTA), 4mL

  
ACD whole blood
  

Yellow ACD (A or B)

 

 

  

Yellow ACD (A or B)

  

Ambient (preferred) - 28 days

Refrigerated - 28 days

  
  • Hemolysis
  • Frozen specimen
  
Esoterix Endocrinology (804008) via LabCorp (504008): R-NX
  
Varies
  
28 - 36 days
  

Polymerase Chain Reaction (PCR) of targeted RET gene exons, DNA sequencing of those PCR products

  

An interpretive report will be provided

  

Germline mutations in the RET gene on chromosome 10 are causative for multiple endocrine neoplasia, type 2 (MEN2), a monogenic, autosomal-dominant hereditary cancer syndrome. The vast majority (>95%) of MEN2 cases have RET gene mutations in exons 10, 11, 13, 14, 15, or 16. MEN2 is characterized by the development of medullary thyroid carcinoma (MTC) and sometimes includes pheochromocytoma (PHEO) and hyperparathyroidism (HPT).

  
81405
  
Result UNLOINC
  
05/24/2019
  
06/28/2021
  
06/28/2021